MedImmune Ventures

MedImmune Ventures was the wholly-owned corporate venture capital arm of AstraZeneca, founded in 2002 and headquartered in Gaithersburg, Maryland. The fund managed $400 million in an evergreen structure following AstraZeneca's commitment of an additional $100 million in November 2011. Senior Managing Director Ron Laufer led a team of three partners. Since 2009, the fund operated as a true evergreen vehicle, recycling proceeds from liquidated investments into new portfolio companies rather than returning capital to LPs on a fixed timeline. MedImmune Ventures focused on equity investments in private companies developing small and large molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging, and healthcare IT related to pharmaceutical product discovery and commercialization. Therapeutic areas covered infectious diseases, cancer, inflammatory diseases, cardiovascular and metabolic disorders, pain and central nervous system conditions, and gastrointestinal disease. The fund leads rounds. Across approximately 65 investments, the portfolio produced 4 IPOs and 11 acquisitions. Notable holdings include G1 Therapeutics (MedImmune led a $12.5 million Series A in October 2013 and the company later completed a $105 million Nasdaq IPO), Melinta Therapeutics, Astria Therapeutics, and Xencor. The fund also co-led a financing round in NeuProtect Pty Ltd, an Australian cardioprotectant company, alongside Starfish Ventures. MedImmune Ventures is now permanently closed and liquidated. During its active years, the fund served a dual mandate: generating financial returns for AstraZeneca while sourcing strategic intelligence about emerging biotech platforms across areas aligned with the parent company's therapeutic priorities. The evergreen structure allowed for patient capital deployment matched to the long development timelines of biopharmaceutical companies.